Courtney Davis Dr Courtney Davis Academics Supervisors Reader in Global Health and Social Medicine Research subject areas Biomedical and life sciences Medicine Policy Contact details +44 (0)20 7848 2720 courtney.davis@kcl.ac.uk
Putting patients first in medicines regulation? Naci, H., Forrest, R. & Davis, C., 30 Nov 2021, In: The BMJ. 375, n2883. Research output: Contribution to journal › Editorial › peer-review. DOIs: https://doi.org/10.1136/bmj.n2883 Data Transparency and Pharmaceutical Regulation in Europe: Road to Damascus, or Room without a View? Davis, C., Mulinari, S. & Jefferson, T., 2021, Transparency, Power, and Influence in the Pharmaceutical Industry: Policy Gain or Confidence Game?. Fierlbeck, K., Graham, J. & Herder, M. (eds.). University of Toronto Press, p. 63-94 Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review Failure of Responsive Regulation?: Pharmaceutical Marketing, Corporate Impression Management and Off-Label Promotion of Enzalutamide in Europe Mulinari, S., Davis, C. & Ozieranski, P., 2021, In: Journal of White Collar and Corporate Crime. 2, 2, p. 69-80 12 p. Research output: Contribution to journal › Article › peer-review Achieving greater independence from commercial influence in research Lexchin, J., Bero, L. A., Davis, C. & Gagnon, M. A., 9 Mar 2021, In: The BMJ. 372, n370. Research output: Contribution to journal › Review article › peer-review. DOIs: https://doi.org/10.1136/bmj.n370 Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States Salcher-Konrad, M., Naci, H. & Davis, C., Dec 2020, In: Milbank Quarterly. 98, 4, p. 1219-1256 38 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1111/1468-0009.12476 International and Temporal Comparative Analysis of UK and US Drug Safety Regulation in Changing Political Contexts Abraham, J. & Davis, C., 30 Jun 2020, In: Social Science & Medicine. 255, 0, 10 p., 113005. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1016/j.socscimed.2020.113005 Inappropriate use of progression-free survival in cancer drug approvals Naci, H. & Davis, C., 10 Mar 2020, In: BMJ (Clinical research ed.). 368, p. m770 Research output: Contribution to journal › Editorial › peer-review. DOIs: https://doi.org/10.1136/bmj.m770 The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza Mulinari, S. & Davis, C., 1 Feb 2020, In: SOCIAL STUDIES OF SCIENCE. 50, 1, p. 145-169 25 p. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1177/0306312719890015 Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis Naci, H., Davis, C., Savović, J., Higgins, J. P. T., Sterne, J. A. C., Gyawali, B., Romo-Sandoval, X., Handley, N. & Booth, C. M., 18 Sep 2019, In: BMJ (Clinical research ed.). 366, p. l5221 l5221. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1136/bmj.l5221 Regulatory scientists' work has important ramifications for public health and should be open to public scrutiny Mulinari, S. & Davis, C., 15 Nov 2018, In: Health Research Policy and Systems. 16, 1, 98. Research output: Contribution to journal › Article › peer-review. DOIs: https://doi.org/10.1186/s12961-018-0371-4 View all publications
30 March 2023 Cancer drug leaflets lack vital information for patients Important information outlining the benefits and related uncertainties of cancer drugs is frequently…